Works matching IS 03407004 AND DT 2024 AND VI 73 AND IP 8
Results: 25
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03728-z
- By:
- Publication type:
- Article
Efficacy and safety of immune checkpoint inhibitors in solid tumor patients combined with chronic coronary syndromes or its risk factor: a nationwide multicenter cohort study.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03747-w
- By:
- Publication type:
- Article
Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03745-y
- By:
- Publication type:
- Article
Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03743-0
- By:
- Publication type:
- Article
MB2033, an anti-PD-L1 × IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicity.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03742-1
- By:
- Publication type:
- Article
Two nomograms constructed for predicting the efficacy and prognosis of advanced non‑small cell lung cancer patients treated with anti‑PD‑1 inhibitors based on the absolute counts of lymphocyte subsets.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03738-x
- By:
- Publication type:
- Article
SIRPG expression positively associates with an inflamed tumor microenvironment and response to PD-1 blockade.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03737-y
- By:
- Publication type:
- Article
Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03735-0
- By:
- Publication type:
- Article
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03734-1
- By:
- Publication type:
- Article
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03733-2
- By:
- Publication type:
- Article
Combination of STING agonist with anti-vascular RGD-(KLAKLAK)<sub>2</sub> peptide as a novel anti-tumor therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03732-3
- By:
- Publication type:
- Article
Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03731-4
- By:
- Publication type:
- Article
USP47 deficiency in mice modulates tumor infiltrating immune cells and enhances antitumor immune responses in prostate cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03730-5
- By:
- Publication type:
- Article
Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03729-y
- By:
- Publication type:
- Article
Prognostic value of genomic mutation signature associated with immune microenvironment in southern Chinese patients with esophageal squamous cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03725-2
- By:
- Publication type:
- Article
Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03724-3
- By:
- Publication type:
- Article
Evaluation of the clinical application value of cytokine expression profiles in the differential diagnosis of prostate cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03723-4
- By:
- Publication type:
- Article
Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03721-6
- By:
- Publication type:
- Article
Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03720-7
- By:
- Publication type:
- Article
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03719-0
- By:
- Publication type:
- Article
Enhanced abscopal anti-tumor response via a triple combination of thermal ablation, IL-21, and PD-1 inhibition therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03718-1
- By:
- Publication type:
- Article
A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03713-6
- By:
- Publication type:
- Article
The biological roles of CD47 in ovarian cancer progression.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03708-3
- By:
- Publication type:
- Article
Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03706-5
- By:
- Publication type:
- Article
The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 8, p. 1, doi. 10.1007/s00262-024-03701-w
- By:
- Publication type:
- Article